vt3989
vivace therapeutics
['lcsm,(-blcsm)', 'mesothelioma', 'vt3989']
first-in-class, fih phase i trial of vt3989 (yap/tead inhibitor) by dr. timothy "yap". impressive response in patients with malignant mesothelioma with nf2 mutations. nf2 mutation (inactivation) is frequent in mesothelioma. #aacr23 #lcsm 
Medical Oncologist, National Cancer Center Hospital, Lung Cancer Study Group @JCOG_official, Educational Committee @JSMO_official, @JLCS_OFFICIAL, @IASLC